US-China tariff conflict prompts multinational firms to mull independent supply chains

Posted on July 5, 2024   |  

AstraZeneca plans to build new manufacturing plants in China amid rising tensions in the US-China tariff dispute.

This move by AstraZeneca shows a shift towards setting up separate supply chains for the US and China markets.

Logistics specialists focusing on China view AstraZeneca's investment as a potential protection against disruptions caused by tariffs.

Industries affected by the tariff conflict have experienced reduced exports, increasing pressure on logistics profitability.

Businesses returning to China, like AstraZeneca's expansion, could bring new life to the logistics industry.

Creating independent supply chains in China benefits both foreign companies and the Chinese government.

This initiative is expected to stimulate economic activity, strengthen logistics capabilities, and promote growth in related sectors and nearby regions.